Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.36 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12581708 | 0.84 | CYP3A4 (0.46) | ERN1PRKDCALDH1A1MAPTCYP3A4 | |
| SCHEMBL31189003 | 0.84 | MEN1 (0.37) | ERN1PRKDCALDH1A1LMNAALDH2 | |
| SCHEMBL29923677 | 0.84 | ALDH1A1 (0.38) | ERN1PRKDCALDH1A1LMNAALDH2 | |
| SCHEMBL16207565 | 0.84 | ERN1 (0.34) | ERN1PRKDCALDH1A1LMNAALDH2 | |
| SCHEMBL12581710 | 0.81 | PRKDC (0.53) | ERN1PRKDCALDH1A1LMNAMAPT | |
| SCHEMBL31426082 | 0.81 | ERN1 (0.33) | ERN1PRKDCALDH1A1LMNAALDH2 | |
| SCHEMBL607199 | 0.80 | ALDH1A1 (0.41) | ERN1PRKDCALDH1A1LMNAMAPT | |
| SCHEMBL3185596 | 0.78 | ERN1 (0.50) | ERN1PRKDCALDH1A1LMNACYP3A4 | |
| SCHEMBL31019366 | 0.75 | ALDH1A1 (0.39) | ERN1ALDH1A1LMNAMAPTCYP3A4 | |
| SCHEMBL23658839 | 0.74 | ERN1 (0.54) | ERN1PRKDCALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121586713-A | Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases | 百济神州(苏州)生物科技有限公司 | 2026-02-27 | — | — | CN | disclosed |
| WO-2025021217-A1 | QUINOLINE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-01-30 | — | — | WO | disclosed |
| US-20240262822-A1 | WDR5 INHIBITORS AND MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | disclosed |
| EP-4055013-B1 | WDR5 INHIBITORS AND MODULATORS | UNIV VANDERBILT (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4334305-A1 | WDR5 INHIBITORS AND MODULATORS | Vanderbilt University (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4090660-B1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-31 | — | — | EP | disclosed |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-12-15 | — | — | US | disclosed |
| EP-4090660-A1 | QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2022-11-23 | — | — | EP | disclosed |
| WO-2022236101-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-1869003-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| US-20070265326-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | US | disclosed |
| US-20070265326-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | US | disclosed |
| US-20070265326-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-15 | — | — | US | disclosed |
| WO-2007122165-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | WO | disclosed |
| EP-1732533-A1 | THYROID RECEPTOR AGONISTS | KARO BIO AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| EP-1732532-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF THE THYROID RECEPTOR | KARO BIO AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006108699-A1 | INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2005092316-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS COMPRISING AGONISTS OF THE THYROID RECEPTOR | KARO BIO AB (SE) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092317-A1 | THYROID RECEPTOR AGONISTS | KARO BIO AB (SE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262822-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | ERN1 1405/4885PRKDC 2946/4885ALDH1A1 3561/4885 |
| US-20220396578-A1 | QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | ERN1 4001/4885PRKDC 4028/4885ALDH1A1 1617/4885 |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | ERN1 1915/4885PRKDC 3268/4885ALDH1A1 3815/4885 |
| US-20070265326-A1 | NOVEL COMPOUNDS | CCL11, MRGPRX2, LTB4R2 | ERN1 3742/4885PRKDC 4644/4885ALDH1A1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.